Sirona Biochem was founded in 2009 by its current Chairman and CEO, Dr. Howard Verrico. The Company’s first transaction was to acquire an exclusive global license to TFChem’s proprietary diabetes drug, the SGLT2 Inhibitor.

Sirona Biochem has expertise in the development of carbohydrate-based molecules.  Essential to life, carbohydrates, or sugar molecules, have broad potential for ground-breaking pharmaceutical and cosmetic development as they play a critical role in most of the major diseases. Carbohydrates

Welcome to Aktieporteføljens “Next Generation Strategic IR”

The future for all listed companies

This showroom shows selected listed companies toward Danish investors. If you are a listed company and would like to know more about what we can offer you Aktieporteføljen see here.


Showcase your company 

For USD 5,000 for a whole year you will be showcased towards Scandinavia's largest investor community. 


Discover & chat 1-to-1 with listed companies for free

You can follow company profiles, products and services, read their news and watch the their videos. At the following dates the showroom will be LIVE and you can chat 1-to-1 with the shown companies. 

1. April

1. August

1. October